Personalized cancer medicine: Biomarkers for cancer of the bile duct

  • Improving the diagnosis of cholangiocellular carcinoma (CCC) by means of immunohistochemistry
  • Better and earlier diagnostics
  • Permitting patients to be already treated in the early stages of the disease

Solution approach:
The current biomarkers for CCC are not specific enough. No test achieves a specificity of anywhere near 100 % with a still acceptable sensitivity. As every individual tumour illness is rare in relation to the total population, the limited specificity means that a large proportion of the positive results are false. The new biomarkers can serve to improve the diagnosis of CCC in tissue and potentially also in bodily fluids. Ethical problems arising from the unnecessary psychological stress posed to the person by false positive results can be reduced in connection with this, as well as the high financial cost of follow-up examinations.

Application areas:
One possible application for this invention is its use as a diagnostic test.

Patent status:
Application: EP (ref.: 14 781 819.9)

References:
Padden, J.; Ahrens, M.; Kälsch, J.; Bertram, S.; Megger, DA.; Bracht, T.; Eisenacher, M.; Kocabayoglu, P.; Meyer, HE.; Sipos, B.; Baba, HA.; Sitek, B.; Immunohistochemical Markers Distinguishing Cholangiocellular Carcinoma from Pancreatic Ductal Adenocarcinoma Discovered by Proteomic Analysis of Microdissected Cells., Mol Cell Proteomics. 2015 Dec 7. pii: mcp.M115.054585

Padden, J.; Megger, DA.; Bracht, T.; Reis, H.; Ahrens, M.; Kohl, M.; Eisenacher, M.; Schlaak, JF.; Canbay, AE.; Weber, F.; Hoffmann, AC.; Kuhlmann, K.; Meyer, HE.; Baba, HA.; Sitek, B.; Identification of novel biomarker candidates for the immunohistochemical diagnosis of cholangiocellular carcinoma., Mol Cell Proteomics. 2014 Oct; 13(10):2661-72